A Clinical Study Aims to Assess the Consistency of Clinical Efficacy in Gastric Cancer Treatment and Drug Susceptibility Outcomes Using a Novel Drug Susceptibility Testing Method
NCT06100003
Summary
The study is a real-world observational clinical study. Patients diagnosed as gastric cancer through histopathology were screened and enrolled. Before anti-tumor treatment, gastroscopy biopsy tissue specimens, surgical specimens, and malignant pleural effusion or ascites specimens, etc. are collected. The investigators will perform a drug sensitivity testing based on a novel drug susceptibility testing method to test the commonly used anti-tumor treatment regimens. Patients were given conventional anti-tumor treatment according to the medical judgment of the doctors. Finally, the investigator will evaluate the consistency of clinical efficacy in gastric cancer treatment and drug susceptibility outcomes.
Eligibility
Inclusion Criteria: 1. Male or female, aged ≥ 18 and ≤80; 2. Patients with gastric cancer diagnosed by histopathology; 3. Patients who need neoadjuvant treatment; adjuvant therapy after radical surgery or palliative treatment; 4. Fresh tumor tissue specimens or malignant pleural effusion or ascites can be obtained; 5. Patients who sign the informed consent form, and are able to comply with the study period treatment process. Exclusion Criteria: 1. Inability to follow the research protocol; 2. Inability to obtain relevant fresh specimens by biopsy/surgery/puncture; 3. Concomitant contraindications to chemotherapy; 4. pregnant or lactating women; 5. Patients deemed inappropriate by investigators.
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06100003